Payment overview · 2025
General Payments
$292.82
17 reported records · 10 companies
Healthcare provider profile · identity verified
Shirley K. Gibson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ALBANY, KY · NPI 1770509713
Verified facts
What the public records show
CMS Open Payments records show Shirley K. Gibson, MD received $292.82 in general payments during 2025 across 17 reported records.
PFIZER INC. accounted for 25.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.95 | 25.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.86 | 13.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.22 | 10.0% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.94 | 9.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.88 | 9.9% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.02 | 8.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.58 | 6.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.94 | 6.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.54 | 5.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.89 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $292.82 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $60.10 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $46.10 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $28.94 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 124 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
158 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
124 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 471 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 460 | 67 |
| Lisinopril | Lisinopril | 324 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 321 | 52 |
| Losartan Potassium | Losartan Potassium | 262 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 260 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 260 | 39 |
| Metformin Hcl | Metformin Hcl | 259 | 40 |
| Atenolol | Atenolol | 217 | 29 |
| Meloxicam | Meloxicam | 189 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 175 | 26 |
| Furosemide | Furosemide | 174 | 31 |
| Trazodone Hcl | Trazodone Hcl | 173 | 22 |
| Gabapentin | Gabapentin | 170 | 27 |
| Jardiance | Empagliflozin | 158 | 28 |
| Potassium Chloride | Potassium Chloride | 157 | 24 |
| Celecoxib | Celecoxib | 148 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 22 |
| Januvia | Sitagliptin Phosphate | 146 | 17 |
| Prednisone | Prednisone | 143 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 137 | 18 |
| Lorazepam | Lorazepam | 136 | 22 |
| Simvastatin | Simvastatin | 126 | 20 |
| Eliquis | Apixaban | 124 | 18 |
| Omeprazole | Omeprazole | 123 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 21 |
| Montelukast Sodium | Montelukast Sodium | 116 | 19 |
| Clonazepam | Clonazepam | 109 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 105 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 101 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 17 |
| Diazepam | Diazepam | 96 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 89 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 85 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 24 |
| Ondansetron Odt | Ondansetron | 85 | 35 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 84 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 27 |
| Fenofibrate | Fenofibrate Nanocrystallized | 78 | suppressed |
| Carvedilol | Carvedilol | 75 | 15 |
| Pregabalin | Pregabalin | 75 | 13 |
| Tramadol Hcl | Tramadol Hcl | 72 | 16 |
| Meclizine Hcl | Meclizine Hcl | 66 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | suppressed |
| Amoxicillin | Amoxicillin | 64 | 53 |
| Glipizide Er | Glipizide | 63 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 62 | suppressed |
| Spironolactone | Spironolactone | 61 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 60 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | suppressed |
| Allopurinol | Allopurinol | 57 | suppressed |
| Famotidine | Famotidine | 52 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 11 |
| Memantine Hcl | Memantine Hcl | 50 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 50 | suppressed |
| Levofloxacin | Levofloxacin | 48 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Fluconazole | Fluconazole | 47 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 43 | suppressed |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Nifedipine Er | Nifedipine | 42 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 42 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 33 |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Ibuprofen | Ibuprofen | 37 | 11 |
| Baclofen | Baclofen | 36 | suppressed |
| Lansoprazole | Lansoprazole | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 35 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Telmisartan | Telmisartan | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | 15 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Cefdinir | Cefdinir | 28 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Nystatin | Nystatin | 27 | 20 |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | suppressed |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Glyburide | Glyburide | 25 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Nabumetone | Nabumetone | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 13 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 18 |
| Glimepiride | Glimepiride | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Invokana | Canagliflozin | 18 | suppressed |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 16 |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Novolin N | Insulin Nph Human Isophane | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Sulindac | Sulindac | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Misoprostol | Misoprostol | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $292.82 · 17 records | PFIZER INC. | Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FANAPT, FARXIGA, GVOKE HYPOPEN, MOUNJARO, NURTEC ODT, PAXLOVID, REXULTI, The Cologuard Plus Collection Kit, VRAYLAR, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error